The UK’s Competition Appeal Tribunal has upheld the Competition and Markets Authority (CMA) decision that GlaxoSmithKline and some generic suppliers of the anti-depressant paroxetine broke competition law. The Competition Appeal Tribunal (Tribunal) has, however, imposed reduced fines of £27.1 million (US$38.26 million) on the firms involved.
Paroxetine is relied on by patients to relieve symptoms of depression. GlaxoSmithKline had agreed to make payments totalling £50 million (US$70.59 million) to other generic suppliers of paroxetine, including Generics Limited and Alpharma Limited, in settlement of patent litigation.
In a decision issued in 2016, the CMA found that these payments were aimed at delaying the potential entry of these competitors supplying generic medicines into the UK market and were unlawful. The CMA imposed fines totalling £44.99 million (US$63.52 million) on the companies directly involved in the infringements – and, where relevant, on their parent companies or successors to these companies.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI